Vanessa Lopes-Rodrigues, Pia Boxy, Eunice Sim, Dong Ik Park, Michael Habeck, Josep Carbonell, Annika Andersson, Diana Fernández-Suárez, Poul Nissen, Anders Nykjær, Lilian Kisiswa
Cytosine arabinoside (AraC) is one of the main therapeutic treatments for several types of cancer, including acute myeloid leukaemia. However, after a high-dose AraC chemotherapy regime, patients develop severe neurotoxicity and cell death in the central nervous system leading to cerebellar ataxia, dysarthria, nystagmus, somnolence and drowsiness. AraC induces apoptosis in dividing cells. However, the mechanism by which it leads to neurite degeneration and cell death in mature neurons remains unclear. We hypothesise that the upregulation of the death receptor p75NTR is responsible for AraC-mediated neurodegeneration and cell death in leukaemia patients undergoing AraC treatment...
July 17, 2023: Cell Death & Disease